Načítá se...
Pembrolizumab-induced Myositis in the Setting of Metastatic Melanoma: An Increasingly Common Phenomenon
Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody, has demonstrated efficacy in treating metastatic melanoma. However, a handful of case reports have been published reporting autoimmune phenomena weeks after administration of the first dose of this immunomodulator. Although immu...
Uloženo v:
| Vydáno v: | J Clin Aesthet Dermatol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Matrix Medical Communications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7442312/ https://ncbi.nlm.nih.gov/pubmed/32884619 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|